Benign Prostatic Hyperplasia is one of the most important disease with a high frequency in urology. There is no doubt that the main stream of treatment is transurethral resection of the prostate, however, rnarked improvement in drug therapy has
been
observed in recent years.
Allylestrenol is a synthetic gestagen which was known to act directly on the prostate to exhibit its effect of reducing the size of the prostate by inhibiting the selective uptake of serum testosterone, inhibition of metabolism of testosterone to
5α-DHT(dihydrotestosterone) reductase, inhibition of 5α-DHT receptor binding.
Our present study was carried out on 108 patients with benign prostatic hyperplasia to evaluate the efficacy and safety of antiandrogen therapy with allylestrenol.
Allylestrenol was administered in a dose of 25mg twice a day in the morning and evening after meal for 12 weeks to the patients and its efficacy was evaluated with peak urinary flow rate, Madsen Symptom Score at 4, 12 weeks after treatment and
prostate
volume at 12 weeks after treatment.
Of these patients 46 completed the study and only 2 patients withdrew from the study owing to side effects. However, these side effects were not serious.
At baseline (mean±SD) the mean peak urinary flow rate was 11.0±3.7 ml/sec, mean symptom score 10.2±4.0 and mean ultrasonic assessment of prostatic volume 36.8±9.6gm. At 4 weeks after treatment (mean±SD) mean peak urinary flow rate was
12±3.5ml/sec, mean symptom score 7.7±4.2 (p>0.05, p<0.05). At 12 weeks after treatment(mean±SD) mean peak urinary flow rate was 12.8±4.7ml/sec, mean symptom score 7.0±4.2 and mean ultrasonic assessment of prostatic volume 36.6±9.3gm(p<0.05,
p<0.05, p>0.05).
|